Cargando…

Structure-based assessment and druggability classification of protein–protein interaction sites

The featureless interface formed by protein–protein interactions (PPIs) is notorious for being considered a difficult and poorly druggable target. However, recent advances have shown PPIs to be druggable, with the discovery of potent inhibitors and stabilizers, some of which are currently being clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzyoud, Lara, Bryce, Richard A., Al Sorkhy, Mohammad, Atatreh, Noor, Ghattas, Mohammad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106675/
https://www.ncbi.nlm.nih.gov/pubmed/35562538
http://dx.doi.org/10.1038/s41598-022-12105-8
_version_ 1784708344856969216
author Alzyoud, Lara
Bryce, Richard A.
Al Sorkhy, Mohammad
Atatreh, Noor
Ghattas, Mohammad A.
author_facet Alzyoud, Lara
Bryce, Richard A.
Al Sorkhy, Mohammad
Atatreh, Noor
Ghattas, Mohammad A.
author_sort Alzyoud, Lara
collection PubMed
description The featureless interface formed by protein–protein interactions (PPIs) is notorious for being considered a difficult and poorly druggable target. However, recent advances have shown PPIs to be druggable, with the discovery of potent inhibitors and stabilizers, some of which are currently being clinically tested and approved for medical use. In this study, we assess the druggability of 12 commonly targeted PPIs using the computational tool, SiteMap. After evaluating 320 crystal structures, we find that the PPI binding sites have a wide range of druggability scores. This can be attributed to the unique structural and physiochemical features that influence their ligand binding and concomitantly, their druggability predictions. We then use these features to propose a specific classification system suitable for assessing PPI targets based on their druggability scores and measured binding-affinity. Interestingly, this system was able to distinguish between different PPIs and correctly categorize them into four classes (i.e. very druggable, druggable, moderately druggable, and difficult). We also studied the effects of protein flexibility on the computed druggability scores and found that protein conformational changes accompanying ligand binding in ligand-bound structures result in higher protein druggability scores due to more favorable structural features. Finally, the drug-likeness of many published PPI inhibitors was studied where it was found that the vast majority of the 221 ligands considered here, including orally tested/marketed drugs, violate the currently acceptable limits of compound size and hydrophobicity parameters. This outcome, combined with the lack of correlation observed between druggability and drug-likeness, reinforces the need to redefine drug-likeness for PPI drugs. This work proposes a PPI-specific classification scheme that will assist researchers in assessing the druggability and identifying inhibitors of the PPI interface.
format Online
Article
Text
id pubmed-9106675
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91066752022-05-15 Structure-based assessment and druggability classification of protein–protein interaction sites Alzyoud, Lara Bryce, Richard A. Al Sorkhy, Mohammad Atatreh, Noor Ghattas, Mohammad A. Sci Rep Article The featureless interface formed by protein–protein interactions (PPIs) is notorious for being considered a difficult and poorly druggable target. However, recent advances have shown PPIs to be druggable, with the discovery of potent inhibitors and stabilizers, some of which are currently being clinically tested and approved for medical use. In this study, we assess the druggability of 12 commonly targeted PPIs using the computational tool, SiteMap. After evaluating 320 crystal structures, we find that the PPI binding sites have a wide range of druggability scores. This can be attributed to the unique structural and physiochemical features that influence their ligand binding and concomitantly, their druggability predictions. We then use these features to propose a specific classification system suitable for assessing PPI targets based on their druggability scores and measured binding-affinity. Interestingly, this system was able to distinguish between different PPIs and correctly categorize them into four classes (i.e. very druggable, druggable, moderately druggable, and difficult). We also studied the effects of protein flexibility on the computed druggability scores and found that protein conformational changes accompanying ligand binding in ligand-bound structures result in higher protein druggability scores due to more favorable structural features. Finally, the drug-likeness of many published PPI inhibitors was studied where it was found that the vast majority of the 221 ligands considered here, including orally tested/marketed drugs, violate the currently acceptable limits of compound size and hydrophobicity parameters. This outcome, combined with the lack of correlation observed between druggability and drug-likeness, reinforces the need to redefine drug-likeness for PPI drugs. This work proposes a PPI-specific classification scheme that will assist researchers in assessing the druggability and identifying inhibitors of the PPI interface. Nature Publishing Group UK 2022-05-13 /pmc/articles/PMC9106675/ /pubmed/35562538 http://dx.doi.org/10.1038/s41598-022-12105-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Alzyoud, Lara
Bryce, Richard A.
Al Sorkhy, Mohammad
Atatreh, Noor
Ghattas, Mohammad A.
Structure-based assessment and druggability classification of protein–protein interaction sites
title Structure-based assessment and druggability classification of protein–protein interaction sites
title_full Structure-based assessment and druggability classification of protein–protein interaction sites
title_fullStr Structure-based assessment and druggability classification of protein–protein interaction sites
title_full_unstemmed Structure-based assessment and druggability classification of protein–protein interaction sites
title_short Structure-based assessment and druggability classification of protein–protein interaction sites
title_sort structure-based assessment and druggability classification of protein–protein interaction sites
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106675/
https://www.ncbi.nlm.nih.gov/pubmed/35562538
http://dx.doi.org/10.1038/s41598-022-12105-8
work_keys_str_mv AT alzyoudlara structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites
AT brycericharda structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites
AT alsorkhymohammad structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites
AT atatrehnoor structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites
AT ghattasmohammada structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites